The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug-Drug Interaction Study

被引：12
|
作者：
Oo, Charles [1 ]
Chen, Chi [1 ]
机构：
[1] Asubio Pharmaceut Inc, Rochelle Pk, NJ 07662 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2009年 / 49卷 / 03期
关键词：
PHARMACOKINETICS; PREDICTION;
D O I：
10.1177/0091270008325931
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：368 / 369
页数：2
相关论文
共 33 条
  • [21] Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK plus advanced tumors
    Hurtado, Felipe K.
    de Braud, Filippo
    De Castro Carpeno, Javier
    de Miguel Luken, Maria Jose
    Wang, Ding
    Scott, Jeffrey
    Lau, Yvonne Y.
    McCulloch, Tracey
    Mau-Sorensen, Morten
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (04) : 475 - 486
  • [22] Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
    Gupta, Neeraj
    Hanley, Michael J.
    Venkatakrishnan, Karthik
    Bessudo, Alberto
    Rasco, Drew W.
    Sharma, Sunil
    O'Neil, Bert H.
    Wang, Bingxia
    Liu, Guohui
    Ke, Alice
    Patel, Chirag
    Yeo, Karen Rowland
    Xia, Cindy
    Zhang, Xiaoquan
    Esseltine, Dixie-Lee
    Nemunaitis, John
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (02) : 180 - 192
  • [23] Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug-Drug Interaction in Healthy Volunteers
    Li, Xue-Qing
    Thelingwani, Roslyn Stella
    Bertilsson, Leif
    Diczfalusy, Ulf
    Andersson, Tommy B.
    Masimirembwa, Collen
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (06):
  • [24] A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects
    Pierre-Eric Juif
    Margaux Boehler
    Yves Donazzolo
    Shirin Bruderer
    Jasper Dingemanse
    European Journal of Clinical Pharmacology, 2017, 73 : 1121 - 1128
  • [25] Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects
    Murase, Katsuyuki
    Lee, Lucy
    Ma, Jiyuan
    Barrett, Rosemary
    Thoolen, Martin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (11) : 1823 - 1831
  • [26] Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects
    Katsuyuki Murase
    Lucy Lee
    Jiyuan Ma
    Rosemary Barrett
    Martin Thoolen
    European Journal of Clinical Pharmacology, 2022, 78 : 1823 - 1831
  • [27] Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
    Tang, Lloyd Wei Tat
    Wu, Guoyi
    Chan, Eric Chun Yong
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2022, 382 (02) : 123 - 134
  • [28] Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling
    Huth, Felix
    Schiller, Hilmar
    Jin, Yi
    Poller, Birk
    Schuhler, Carole
    Weis, Wendy
    Woessner, Ralph
    Drollmann, Anton
    End, Peter
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (01): : 118 - 129
  • [29] Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors
    Guo, Jian
    Zhou, Diansong
    Li, Yan
    Khanh, Bui H.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2015, 36 (08) : 507 - 519
  • [30] Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors
    Felipe K. Hurtado
    Filippo de Braud
    Javier De Castro Carpeño
    Maria Jose de Miguel Luken
    Ding Wang
    Jeffrey Scott
    Yvonne Y. Lau
    Tracey McCulloch
    Morten Mau-Sorensen
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 475 - 486
1234